Select your location.
*e-commerce not available for this region.
Although every cancer patient has the ability to respond to immunotherapy, tumors often fail to regress due to either primary or acquired resistance.
In our interview, Dr. Siwen Hu-Lieskovan, PhD, MD, Director of Solid Tumor Immunotherapy at the Huntsman Cancer Institute, University of Utah discussed the mechanisms behind immune evasion and how this understanding can help create a personalized treatment strategy with the goal of prolonged survival.
For research use only. Not for use in diagnostic procedures.
Expert interview: cancer resistance to immunotherapy